Oct 20, 2021 / 05:00PM GMT
Robert Burns - H.C. Wainwright - Analyst
So for our next presentation, I'm joined by Neil Desai, the Chief Executive Officer of Aadi Bioscience, which is a relatively new company on the precision oncology scene and I'll let Neil go into depth regarding its pipeline. So the generalized format for this one is going to be Neil is going to do a corporate presentation and then I will obviously do some Q-and-A after. If you have questions, you can always email me at [email protected]. And with that, Neil, take it away.
Neil Desai - Aadi Bioscience, Inc. - Founder, CEO & President
Okay, thanks very much, Robert. It is a pleasure to be presenting here today. We are recently a public company and so I have to put up this slide with the forward-looking statements that we might come across.
I'm going to start with a brief summary. So our Company is a late-stage precision oncology company that's reengineering mTOR inhibition and we are focused on the development and commercialization of our compound, FYARRO, which is an albumin-based nanoparticle inhibitor and it
Aadi Bioscience Inc at H C Wainwright Precision Oncology Conference (Virtual) Transcript
Feb 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers